Inotek Pharma (ITEK) Posts Narrwer-than-Expected Q1 Loss of 21c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Inotek Pharmaceuticals Corporation Reports First Quarter 2015 Operational and Financial Results
May 15, 2015 7:00 AM EDTLEXINGTON, Mass.--(BUSINESS WIRE)-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma, today reported financial results and operational highlights for the quarter ended March 31, 2015.
During the first quarter of 2015, Inotek successfully completed its IPO raising gross proceeds of approximately $63 million in the initial public offering combined with a concurrent offering of convertible notes, commented David P. Southwell, President and Chief Executive Officer of Inotek. We are on schedule to initiate our first pivotal Phase 3 trial in the third quarter of 2015,... More
